| __timestamp | HUTCHMED (China) Limited | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 5496000 |
| Thursday, January 1, 2015 | 29829000 | 9786000 |
| Friday, January 1, 2016 | 39578000 | 6792000 |
| Sunday, January 1, 2017 | 43277000 | 7313000 |
| Monday, January 1, 2018 | 48645000 | 8382000 |
| Tuesday, January 1, 2019 | 52934000 | 10803000 |
| Wednesday, January 1, 2020 | 61349000 | 12944000 |
| Friday, January 1, 2021 | 127125000 | 21967000 |
| Saturday, January 1, 2022 | 136106000 | 32810000 |
| Sunday, January 1, 2023 | 133175999 | 46542000 |
Data in motion
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Xenon Pharmaceuticals Inc. and HUTCHMED (China) Limited, from 2014 to 2023. Over this period, HUTCHMED's SG&A expenses surged by approximately 400%, peaking in 2022, while Xenon Pharmaceuticals saw an impressive increase of over 700%, reaching its highest in 2023. This stark contrast highlights HUTCHMED's consistent growth, with a notable spike in 2021, whereas Xenon Pharmaceuticals experienced a more gradual yet significant rise. These trends reflect strategic investments in operational capabilities and market expansion. As the pharmaceutical landscape continues to shift, monitoring such financial metrics offers invaluable insights into corporate strategies and market positioning.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.